Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials

BioDrugs · Published 2026-05-12 · DOI 10.1007/s40259-026-00776-y

Free full text

Authors (15)

Zhihua Ran, Yan Chen, Yinglei Miao, Yufang Wang, Xiang Gao, Jie Zhong, Xueli Ding, Chengdang Wang, Xiaolan Zhang, Yijuan Ding, Naizhong Hu, Dan Tang, Jiao Yu, Chenxi Qian, Jun Shen

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year
2026

Citation

Ran, Z., Chen, Y., Miao, Y., et al. (2026). Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials. BioDrugs. https://doi.org/10.1007/s40259-026-00776-y

Related articles